Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday.

Piper Sandler reaffirmed its positive stance on Inspire Medical Systems (NYSE:NYSE:INSP), maintaining an Overweight rating with a $260.00 price target. The endorsement comes after a steep 14.15% ...

INSPIRE MEDICAL SYSTEMS INC (INSP) is a mid-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 55% based on the firm’s underlying fundamentals and ...

So, Inspire Medical Systems has an ROCE of 1.9%. In absolute terms, that's a low return and it also under-performs the Medical Equipment industry average of 9.6%. In the above chart we have ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Inspire Medical Systems, Inc. announced preliminary fourth quarter and full year 2024 financial results, revealing anticipated revenues of approximately $239.5 million to $239.7 million for Q4 ...

Investing.com -- Shares of Inspire Medical Systems, Inc. (NYSE:INSP) fell 11% today, despite the company announcing preliminary results that exceeded analysts' expectations for the fourth quarter ...

BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion. Shopify Posts Upbeat ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, ...

Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday. Despite the robust preliminary results, the company’s shares plunged nearly ...